Senegal has launched Drepaf, a generic hydroxyurea drug produced locally to treat sickle-cell disease at roughly half the cost of previous therapies [2].
The initiative aims to expand medical access in a region where the financial burden of chronic care often prevents patients from receiving life-saving medication. By lowering the price barrier, the production of Drepaf seeks to improve health outcomes for millions of people across sub-Saharan Africa [1, 2].
Sickle-cell disease affects more than seven million people worldwide [1]. The burden of the condition is heavily concentrated in Africa, where nearly 80% of all patients live [1]. The scale of the crisis is further highlighted by the fact that nearly 400,000 children are born with the disease each year in Africa [3].
Drepaf is a generic version of hydroxyurea, a medication used to reduce the frequency and severity of painful crises associated with the disease. Because the drug is manufactured within Senegal and distributed through local pharmacies, the cost of treatment has been divided by two [2].
This local production model is designed to bypass the high costs associated with importing specialized pharmaceuticals. By creating a sustainable supply chain within the continent, the program aims to provide a consistent, and affordable source of medication for those who previously lacked access due to pricing [1, 2].
Medical providers in the region said that the availability of affordable generics can significantly reduce hospitalizations and improve the quality of life for those living with the genetic blood disorder [1].
“The cost of treatment has been divided by two.”
The introduction of Drepaf represents a shift toward pharmaceutical autonomy in West Africa. By producing generic versions of essential medicines locally, Senegal is challenging the dependency on expensive imports and addressing a critical public health gap for a disease that disproportionately affects the African population.
